Navigation Links
Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Date:10/12/2009

in(TM) be completed prior to regulatory approval. Triapine®, a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it may have to consider curtailing or ceasing operations or liquidating its assets, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM) (laromustine) Injection, delays in the regulatory approval process, particularly for Onrigin(TM) (laromustine) Injection, delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a new randomized trial of Onrigin(TM) prior to regulatory approval in accordance with the recommendation of the Oncologic Drug Advisory Committee, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)... 2014 LSI Medience Corporation today announced ... Kineticos, a Raleigh-Durham, NC ... LSI Medience in identifying opportunities for Presepsin, a ... in clinical trials. The Presepsin biomarker ... of sepsis, prognosis of septic patients, early risk ...
(Date:7/24/2014)... Talyst, a market leader in pharmacy automation, ... State Veterans Homes (NASVH) Summer Conference in ... NASVH is to ensure that each and every eligible ... care and respect which they have earned by their ... Remote Dispensing System, Talyst can help State Veterans Homes ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 8, 2010 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., ... company that develops, manufactures and sells patented biopharmaceutical, ... pharmaceuticals, today announced that the senior management will ... quarter of fiscal year 2011 ending September 30, ...
... Md., Nov. 8, 2010 Substandard and counterfeit versions ... locations across Ghana by the Medicines Quality Monitoring surveillance ... Board (FDB) in collaboration with the U.S. Pharmacopeial Convention ... the program samples antimalarials across the public and private ...
Cached Medicine Technology:Tianyin Pharmaceutical Co., Inc. to Host First Quarter of Fiscal Year 2011 Earnings Conference Call on Thursday, November 11, 2010 at 9:00 a.m. ET 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 2Substandard and Counterfeit Antimalarial Drugs in Ghana Discovered by Cooperative Program of USP, Ghana Food and Drugs Board 3
(Date:7/24/2014)... Members of the Iowa State Board of Health ... of Sales at OutcomesMTM, as their Chairperson. Wolnerman said he ... and that his peers chose to keep him in this ... I can for the citizens of Iowa,” Wolnerman said. “As ... a special insight to concerns and issues related to the ...
(Date:7/24/2014)... BOSTON -- A new study has shown that it is ... by measuring the short-term effects of that same exposure. The ... , will make it possible to develop simpler and cheaper ... , Despite an overall decrease in incidence of ... be diagnosed with the disease in their lifetime, and around ...
(Date:7/24/2014)... PHILADELPHAA rare procedure occasionally performed during Jewish circumcisions that ... herpes simplex virus type 1 (HSV-1) transmissions documented ... review conducted by Penn Medicine researchers and published ... Disease Society found. The reviewers, from Penn,s ... cases in New York, Canada and Israel. , The ...
(Date:7/24/2014)... the Human Papillomavirus Vaccination (HPV) even after becoming ... test results than those who were never vaccinated. ... Transmitted Diseases . , Researchers from Boston ... Medicine conducted a cross-sectional study of 235 women ... testing. HPV status and demographic and behavioral characteristics ...
(Date:7/24/2014)... According to market research report "3D ... Forecasts and Analysis - 2018", the 3D mapping ... $7.7 billion by 2018 at a CAGR of ... data tables and 30 figures spread through 222 ... Global Advancements, Business Models, Technology Roadmap, Forecasts and ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... Effect was especially strong for estrogen-sensitive tumor types, study ... consumed even in small amounts, increases the risk of ... cancer, a new study shows. , The findings, expected ... the American Association for Cancer Research, in San Diego, ...
... (p. 46). Senior Editor David J. Jefferson writes,about the ... Ulysses S.,Grant High School, class of ,82 as part ... former classmates, Jefferson tells the,stories of those who lived ... the first for which divorce was just another part ...
... attacks in their tracks , , SATURDAY, April 12 (HealthDay ... for millions of Americans. , With a bit ... their suffering or perhaps even avoid it altogether, according ... of allergy and clinical immunology at the Saint Louis University ...
... Care, MILLBRAE, Calif., April 11 Healthcare ... second strike at,the facility in two months, in ... workers, proposals to improve care., The three-day ... on Tuesday, April 15.,Caregivers launched a previous, 24-hour ...
... paid but more upset when they owned stock , , ... clinical studies aren,t overly concerned if researchers have financial ... a U.S. study. , "Though peoples, willingness to take ... substantially based on the types of financial disclosures, and ...
... Puerto Ricans have higher rates of depression than other ... new study by researchers at Hebrew SeniorLifes Institute for ... Ricans, who make up 11 percent of the Hispanics ... depression, compared to Mexican Americans, Cuban Americans, and Hispanics ...
Cached Medicine News:Health News:Drinking May Raise Breast Cancer Risk 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Spring and Pollen Are in the Air 2Health News:Clinical Trial Volunteers Uneasy About Some Financial Ties 2Health News:Researchers find disparities in depression among older Hispanics in US 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: